Triadimefon
Based on 1 Customer Validation
Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.12%
- CAS 番号: 43121-43-3
- 分子式: C14H16ClN3O2
- 分子量:293.75
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Antifungal Compound Library
HY-L048
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Pesticide Compound Library
HY-L183
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Environmental Pollutant Compound Library
HY-L247
-
Lactylation Compound Library
HY-L249
AMPK アイソフォーム固有の製品をすべて表示
More
生物活性
|
Akt1 |
Triadimefon (5-50 mg/L) significantly inhibits the growth of Saccharomyces cerevisiae (45%-100% inhibition)[1].
Triadimefon (0.15-0.3 mM; 3 days) significantly reduces albumin production in primary rat hepatocytes and induces a metabolic shift in hepatocytes (from glycolysis to gluconeogenesis and from fatty acid synthesis to fatty acid oxidation)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Saccharomyces cerevisiae CICC 1202
-
Concentration:0.1 mg/L, 1.0 mg/L, 5.0 mg/L, 10 mg/L, 50 mg/L
-
Incubation Time:
-
Result:Did not significantly affect yeast growth at 0.1 mg/L and 1.0 mg/L.
Significantly reduced cell viability, with 45%, 80%, and 100% growth inhibition at 5 mg/L, 10 mg/L, and 50 mg/L, respectively.
Triadimefon (25-100 mg/kg; p.o.; 9 days (GD 12-GD 20)) significantly reduces serum testosterone level, increases the number of fetal Leydig cells with abnormal aggregation in male fetuses, downregulates testis-related gene and protein expression, induces oxidative stress in pregnant Sprague-Dawley rats[5].
Triadimefon (20-200 mg/kg; i.p.; once daily; 7 consecutive days) significantly inhibits spatial learning ability, impairs spatial reference memory, and reduces hippocampal retinoic acid (HY-14649) concentration in rats[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pregnant Sprague-Dawley rats and their male fetuses[2]
-
Dosage:0 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg
-
Administration:Gavage (2 mL/kg); daily; from gestational day (GD) 12 to GD 21 (10 days)
-
Result:Significantly reduced the thickness of zona fasciculata and serum aldosterone level in male fetuses.
Reduced serum corticosterone and ACTH levels.
Showed downregulation of Agtr1, Mc2r, Star, Cyp11b1, Cyp11b2, Igf1, Nr5a1, Sod2, Gpx1, and Cat mRNA.
Reduced AT1R, CYP11B2, IGF1, NR5A1, and MC2R protein levels.
Significantly reduced phosphorylation of AKT1 and ERK1/2.
Significantly increased pAMPK level without affecting total AMPK.
化学情報
-
CAS 番号 43121-43-3
-
性状 Solid
-
分子量 293.75
-
分子式 C14H16ClN3O2
-
Color White to off-white
-
SMILES
CC(C)(C(C(N1N=CN=C1)OC2=CC=C(C=C2)Cl)=O)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 250 mg/mL (851.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (7.08 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (624 KB)
- English - EN (624 KB)
- Français - FR (624 KB)
- Deutsch - DE (624 KB)
- Norwegian - NO (624 KB)
- Español - ES (624 KB)
- Swedish - SV (624 KB)
- Italian - IT (624 KB)
- Korean - KR (624 KB)
- Portuguese - PT (624 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Kong Z, et al. The fungicide triadimefon affects beer flavor and composition by influencing Saccharomyces cerevisiae metabolism. Sci Rep. 2016 Sep 15;6:33552. [Content Brief]
[2]. Xu Q, et al. Triadimefon suppresses fetal adrenal gland development after in utero exposure. Toxicology. 2021 Oct;462:152932. [Content Brief]
[4]. Walker QD, et al. Triadimefon and triadimenol: effects on monoamine uptake and release. Toxicol Appl Pharmacol. 1996 Aug;139(2):227-33. [Content Brief]
[5]. Lin L, et al. Triadimefon increases fetal Leydig cell proliferation but inhibits its differentiation of male fetuses after gestational exposure. Ecotoxicol Environ Saf. 2021 Oct 30;228:112942. [Content Brief]
[6]. Di Renzo F, et al. Stage-dependent abnormalities induced by the fungicide triadimefon in the mouse. Reprod Toxicol. 2011 Feb;31(2):194-9. [Content Brief]
[7]. Xi J, et al. Suppressive effect of triadimefon, a triazole fungicide, on spatial learning and reference memory in rats. Behav Pharmacol. 2012 Dec;23(8):727-34. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4043 mL | 17.0213 mL | 34.0426 mL | 85.1064 mL |
| 5 mM | 0.6809 mL | 3.4043 mL | 6.8085 mL | 17.0213 mL | |
| 10 mM | 0.3404 mL | 1.7021 mL | 3.4043 mL | 8.5106 mL | |
| 15 mM | 0.2270 mL | 1.1348 mL | 2.2695 mL | 5.6738 mL | |
| 20 mM | 0.1702 mL | 0.8511 mL | 1.7021 mL | 4.2553 mL | |
| 25 mM | 0.1362 mL | 0.6809 mL | 1.3617 mL | 3.4043 mL | |
| 30 mM | 0.1135 mL | 0.5674 mL | 1.1348 mL | 2.8369 mL | |
| 40 mM | 0.0851 mL | 0.4255 mL | 0.8511 mL | 2.1277 mL | |
| 50 mM | 0.0681 mL | 0.3404 mL | 0.6809 mL | 1.7021 mL | |
| 60 mM | 0.0567 mL | 0.2837 mL | 0.5674 mL | 1.4184 mL | |
| 80 mM | 0.0426 mL | 0.2128 mL | 0.4255 mL | 1.0638 mL | |
| 100 mM | 0.0340 mL | 0.1702 mL | 0.3404 mL | 0.8511 mL |
Triadimefon 関連分類
HY-123037 関連分類
Powered by Bioz